{"id":745044,"date":"2014-01-13T08:35:00","date_gmt":"2014-01-13T08:35:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/"},"modified":"2023-03-22T00:05:00","modified_gmt":"2023-03-22T04:05:00","slug":"merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<ul>\n<li>         Initiates rolling submission of U.S. Biologics License Application          (BLA) for MK-3475, the company\u2019s anti-PD-1 immunotherapy; expects to          complete application in first half of 2014.       <\/li>\n<li>         Prepares for 2014 regulatory actions for V503, vintafolide (EU),          vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and          AIT-Ragweed; anticipates filing odanacatib, suvorexant.       <\/li>\n<li>         Evaluates the role of Merck\u2019s Animal Health and Consumer Care          businesses in the company\u2019s strategy for long-term value creation;          expects conclusions to be reached and action, if any, to be taken in          2014.       <\/li>\n<li>         Divests assets, including a portion of the U.S. ophthalmics business,          SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc.       <\/li>\n<\/ul>\n<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today will report on the strategic and operating actions it is taking to<br \/>\n      drive short- and long-term growth, including sharpening its focus in<br \/>\n      core markets and therapeutic areas, advancing its innovative pipeline<br \/>\n      and unlocking the value in non-core areas of its business. In October<br \/>\n      2013, Merck announced a multi-year initiative to resource opportunities<br \/>\n      that offer the greatest potential return on investment, improve the<br \/>\n      company\u2019s performance in the short term and create long-term value.\n    <\/p>\n<p>\n      \u201cWe\u2019re taking significant and decisive action to make Merck a more<br \/>\n      competitive company, better positioned to drive innovation and growth,\u201d<br \/>\n      said Kenneth C. Frazier, chairman and chief executive officer, Merck.<br \/>\n      \u201cWe\u2019re pleased with the solid progress we have already made against each<br \/>\n      of our key areas of focus, and we are quickly moving ahead to build on<br \/>\n      this momentum to make Merck a leaner, more agile company focused on the<br \/>\n      best opportunities to create value and advance global health.\u201d\n    <\/p>\n<p>\n      As part of the initiative announced <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fcorporate-news%2Fmerck-announces-global-initiative-sharpen-commercial-and-rd-focus&#038;esheet=50781813&#038;newsitemid=20140113005960&#038;lan=en-US&#038;anchor=last+October&#038;index=1&#038;md5=7efad44c73119fb498e095a4d96178c5\" rel=\"nofollow\">last<br \/>\n      October<\/a>, the company expects to realize a net reduction of annual<br \/>\n      operating expenses of approximately $2.5 billion by the end of 2015 with<br \/>\n      40 percent, or $1.0 billion, to be realized by the end of 2014. These<br \/>\n      savings are off of the company\u2019s full-year 2012 expense levels.\n    <\/p>\n<p>\n      The company continues to make progress on its innovative pipeline and in<br \/>\n      2014 expects to complete its regulatory application for <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmerck-initiates-rolling-submission-us-biologics-license-application-m&#038;esheet=50781813&#038;newsitemid=20140113005960&#038;lan=en-US&#038;anchor=MK-3475&#038;index=2&#038;md5=cf5c3d2ed20d025d0c985afb690c1c28\" rel=\"nofollow\">MK-3475<\/a>,<br \/>\n      the company\u2019s anti-PD-1 immunotherapy, in patients with advanced<br \/>\n      melanoma who have previously been treated with ipilimumab<b>; <\/b>as<br \/>\n      well as applications for odanacatib for osteoporosis; and suvorexant for<br \/>\n      insomnia. The company may also receive regulatory approvals for multiple<br \/>\n      promising candidates, including V503, the company\u2019s 9-valent HPV vaccine<br \/>\n      candidate; vintafolide in the European Union for use in<br \/>\n      platinum-resistant ovarian cancer; vorapaxar for the reduction of<br \/>\n      atherothrombotic events when added to standard of care in patients with<br \/>\n      a history of heart attack and no history of stroke or transient ischemic<br \/>\n      attack; NOXAFIL IV for fungal infections; vaniprevir in Japan for the<br \/>\n      treatment of chronic hepatitis C virus (HCV) infection; and the allergy<br \/>\n      immunotherapies AIT-Grass and AIT-Ragweed.\n    <\/p>\n<p>\n      <span class=\"bwuline\"><b>Core Markets and Commercial Therapeutic Area<br \/>\n      Focus<\/b><\/span>\n    <\/p>\n<p>\n      The company has taken steps to significantly sharpen its focus on select<br \/>\n      core markets and commercial therapeutic areas. Progress since the<br \/>\n      October announcement includes:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Increasing focus on the key markets of the United States, Japan,<br \/>\n        France, Germany, Canada, United Kingdom, China, Brazil, Russia and<br \/>\n        Korea.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Intensifying its portfolio assessment process and recently announcing<br \/>\n        the divestiture of a portion of the company\u2019s U.S. ophthalmics<br \/>\n        business and the sale of the U.S. marketing rights for SAPHRIS.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Consistent with Merck\u2019s new emphasis on its diabetes, acute hospital<br \/>\n        care, vaccines and oncology businesses, the company established its<br \/>\n        integrated oncology business unit and is recruiting external talent<br \/>\n        with deep scientific and commercial experience in oncology to promote<br \/>\n        Merck\u2019s existing portfolio of products, as well as the future launch<br \/>\n        of MK-3475.\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\"><b>Prioritized Pipeline in Focus<\/b><\/span>\n    <\/p>\n<p>\n      Merck continues to prioritize its R&#038;D efforts and focus on candidates<br \/>\n      that it believes represent breakthrough science that will make a<br \/>\n      difference for patients and payers, with increased emphasis on<br \/>\n      externally sourced programs. Progress since the October announcement<br \/>\n      includes:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Initiated the rolling submission of a BLA in the U.S. for MK-3475 in<br \/>\n        patients with advanced melanoma who have previously been treated with<br \/>\n        ipilimumab. A rolling submission allows completed portions of the<br \/>\n        application to be submitted and reviewed by the FDA on an ongoing<br \/>\n        basis. Merck expects to complete its application in the first half of<br \/>\n        2014.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Started additional MK-3475 clinical trials and now has 10 trials in<br \/>\n        more than 10 cancers, including a collaboration with GlaxoSmithKline<br \/>\n        to evaluate MK-3475 in combination with pazopanib<b> <\/b>in advanced<br \/>\n        renal cell carcinoma.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Received Breakthrough Therapy designation for MK-5172\/MK-8742, the<br \/>\n        company\u2019s chronic HCV combination regimen, and advanced the<br \/>\n        combination into Phase IIB in a diverse range of chronic HCV patients.\n      <\/li>\n<\/ul>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Filed vaniprevir (MK-7009), an investigational protease inhibitor for<br \/>\n        the treatment of chronic HCV infection, in Japan.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Initiated Phase III trials for its BACE inhibitor for Alzheimer\u2019s<br \/>\n        disease, MK-8931.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Received priority review status for NOXAFIL IV.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Plans to divest Sirna Therapeutics, Inc. to Alnylam.\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\"><b>Unlocking Value in Non-Core Areas<\/b><\/span>\n    <\/p>\n<p>\n      The company is continuing to evaluate all aspects of how it operates as<br \/>\n      a business and has adopted a streamlined operating model to ensure<br \/>\n      improved allocation of resources to the most critical business areas.<br \/>\n      The company\u2019s goal is for each of its priority business areas to be<br \/>\n      industry leaders.\u00a0The company assesses on an ongoing basis whether<br \/>\n      particular assets are core to its strategy, if they provide strategic<br \/>\n      advantage and whether they would generate greater long-term value as<br \/>\n      part of the company, or not. Progress since the October announcement<br \/>\n      includes:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Exploring strategic options for its Animal Health and Consumer Care<br \/>\n        businesses to determine the most value-creating option for each and<br \/>\n        could reach different decisions about the two businesses. The company<br \/>\n        expects to complete the process and take action, if any, in 2014.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Over the last four months of 2013, the company announced plans to<br \/>\n        close or sell manufacturing operations at Swords, Ireland; La Vall\u00e9e,<br \/>\n        France; Arecibo and Barceloneta, Puerto Rico; and completed the sale<br \/>\n        of its active pharmaceutical ingredient (API) operations at Oss, the<br \/>\n        Netherlands; and announced closure of the Summit, N.J. site.\n      <\/li>\n<\/ul>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50781813&#038;newsitemid=20140113005960&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=b229980624c7fee8e6dbc75c2b03c929\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50781813&#038;newsitemid=20140113005960&#038;lan=en-US&#038;anchor=Twitter&#038;index=4&#038;md5=cd06f43e3bef170811d7834a2e25c0a6\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50781813&#038;newsitemid=20140113005960&#038;lan=en-US&#038;anchor=Facebook&#038;index=5&#038;md5=cd56e1b5a750d131cc344a033f033cc9\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50781813&#038;newsitemid=20140113005960&#038;lan=en-US&#038;anchor=YouTube&#038;index=6&#038;md5=e58258087351b7c42e3fb1b705766cd6\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful.\u00a0If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50781813&#038;newsitemid=20140113005960&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=7&#038;md5=35774ca02ea01a1deffcb0d5eca98e66\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140113005960r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Kelley Dougherty, 908-423-4291<br \/>Steven        Cragle, 908-423-3461<br \/>Investor:<br \/>Carol Ferguson, 908-500-1101<br \/>Justin        Holko, 908-423- 5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company\u2019s anti-PD-1 immunotherapy; expects to complete application in first half of 2014. Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant. Evaluates the role of Merck\u2019s Animal Health and Consumer Care businesses in the company\u2019s strategy for long-term value creation; expects conclusions to be reached and action, if any, to be taken in 2014. Divests assets, including a portion of the U.S. ophthalmics business, SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745044","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company\u2019s anti-PD-1 immunotherapy; expects to complete application in first half of 2014. Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant. Evaluates the role of Merck\u2019s Animal Health and Consumer Care businesses in the company\u2019s strategy for long-term value creation; expects conclusions to be reached and action, if any, to be taken in 2014. Divests assets, including a portion of the U.S. ophthalmics business, SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2014-01-13T08:35:00+00:00\",\"dateModified\":\"2023-03-22T04:05:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference - Merck.com","og_description":"Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company\u2019s anti-PD-1 immunotherapy; expects to complete application in first half of 2014. Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant. Evaluates the role of Merck\u2019s Animal Health and Consumer Care businesses in the company\u2019s strategy for long-term value creation; expects conclusions to be reached and action, if any, to be taken in 2014. Divests assets, including a portion of the U.S. ophthalmics business, SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:05:00+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/","name":"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx","datePublished":"2014-01-13T08:35:00+00:00","dateModified":"2023-03-22T04:05:00+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140113005960r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-accelerated-strategic-actions-for-growth-at-32nd-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fda3c6bf-fca5-420a-bc2b-c8a887d7442e","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745044\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745044"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}